Premium
Detection of residual B precursor lymphoblastic leukemia by uniform gating flow cytometry
Author(s) -
Mejstříková Ester,
Froňková Eva,
Kalina Tomáš,
Omelka Marek,
Batinić Drago,
Dubravčić Klara,
Pospíšilová Klára,
Vášková Martina,
Luria Drorit,
Cheng Suk Hang,
Ng Margaret,
Leung Yonna,
Kappelmayer Janos,
Kiss Flora,
Izraeli Shai,
Stark Batia,
Schrappe Martin,
Trka Jan,
Starý Jan,
Hrušák Ondřej
Publication year - 2010
Publication title -
pediatric blood and cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.116
H-Index - 105
eISSN - 1545-5017
pISSN - 1545-5009
DOI - 10.1002/pbc.22261
Subject(s) - minimal residual disease , medicine , flow cytometry , gating , lymphoblastic leukemia , leukemia , t cell receptor , cutoff , immunophenotyping , predictive value , blood cancer , cytometry , oncology , immunology , cancer , t cell , physiology , physics , immune system , quantum mechanics
Background Residual disease (RD) is an important prognostic factor in acute lymphoblastic leukemia (ALL). Flow cytometry (FC)‐based RD detection is easy to perform, but interpretation requires expert analysis due to individual differences among patients. Procedure We focused at the design of standardized and reproducible RD monitoring in ALL. RD was investigated by a uniform gating strategy, which was designed internationally and tested in one center by Ig/TCR rearrangements. Results For each gate, positivity cutoff value was assigned using quantification of non‐leukemic background. Comparing to Ig/TCR at 0.1% level, 80 of 103 specimens were correctly diagnosed by FC. The predictive value of FC RD at day 15 was then analyzed. In B lineage ALL, day 15 FC significantly correlated with Ig/TCR results at day 33 and/or week 12 ( P < 0.01). No significant correlation was found in T lineage ALL. Conclusions Thus, FC with preset uniform gating at day 15 predicts PCR‐detectable MRD in B precursor ALL. Presented data may be used to define new polychromatic cytometric diagnostics of MRD including semiautomatic assessment. Pediatr Blood Cancer 2010; 54:62–70. © 2009 Wiley‐Liss, Inc.